| Identification | Back Directory | [Name]
Benzamide, N-[(5-chloro-2-propoxyphenyl)methyl]-4-fluoro-N-[2-[4-[(2-propyn-1-ylamino)sulfonyl]phenyl]ethyl]- | [CAS]
3037332-85-4 | [Synonyms]
Benzamide, N-[(5-chloro-2-propoxyphenyl)methyl]-4-fluoro-N-[2-[4-[(2-propyn-1-ylamino)sulfonyl]phenyl]ethyl]- | [Molecular Formula]
C28H28ClFN2O4S | [MOL File]
3037332-85-4.mol | [Molecular Weight]
543.05 |
| Chemical Properties | Back Directory | [Boiling point ]
697.6±65.0 °C(predicted) | [density ]
1.283±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | [pka]
9.30±0.50(predicted) |
| Hazard Information | Back Directory | [Uses]
MS-II-124 is an effective and selective NLRP3 inhibitor (IC50=0.12 μM) with anti-inflammatory and immunomodulatory activities, which can be used in the research of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS)[1]. | [in vivo]
MS-II-124 (10 mg/kg; i.p.; single dose) reduces lung inflammation and immune cell infiltration in the LPS (HY-D1056) ( i.n. instillation, 40 μg in 40 μL PBS) -induced ALI/ARDS wild-type mouse model, exhibiting anti-inflammatory and immunomodulatory activities[1]. | Animal Model: | ALI/ARDS WT C57BL/6 mice model[1]. | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection (i.p.), Single dose. 1 h before i.n. instillation of LPS (40 μg in 40 μL PBS). | | Result: | Significantly inhibited lipopolysaccharide (LPS)-induced IL-1β production in pulmonary bronchoalveolar lavage fluid (BALF), whereas NLRP3 deletion did not significantly inhibit its production. |
| [References]
[1] Xu Y, et al. Characterization of a small molecule inhibitor of the NLRP3 inflammasome and its potential use for acute lung injury[J]. Bioorganic Chemistry, 2024: 107562. DOI:10.1016/j.bioorg.2024.107562 |
|
|